Year: 2017
Type: article
Abstract: BACKGROUND: Chronic obstructive pulmonary disease (COPD) is characterized by chronic bronchitic and emphysematous components. In one biophysical model, the concentration of mucin on the airway surfaces is hypothesized to be a key variable that controls mucus transport in healthy persons versus cessation of transport in persons with muco-obstructive lung diseases. Under this model, it is postulated that a high mucin concentration produces the sputum and disease progression that are characteristic of chronic bronchitis. METHODS: We characterized the COPD status of 917 participants from the Subpopulations and Intermediate Outcome Measures in COPD Study (SPIROMICS) using questionnaires administered to participants, chest tomography, spirometry, and examination of induced sputum. Total mucin concentrations in sputum were measured with the use of size-exclusion chromatography and refractometry. In 148 of these participants, the respiratory secreted mucins MUC5AC and MUC5B were quantitated by means of mass spectrometry. Data from chronic-bronchitis questionnaires and data on total mucin concentrations in sputum were also analyzed in an independent 94-participant cohort. RESULTS: Mean (±SE) total mucin concentrations were higher in current or former smokers with severe COPD than in controls who had never smoked (3166±402 vs. 1515±152 μg per milliliter) and were higher in participants with two or more respiratory exacerbations per year than in those with zero exacerbations (4194±878 vs. 2458±113 μg per milliliter). The absolute concentrations of MUC5B and MUC5AC in current or former smokers with severe COPD were approximately 3 times as high and 10 times as high, respectively, as in controls who had never smoked. Receiver-operating-characteristic curve analysis of the association between total mucin concentration and a diagnosis of chronic bronchitis yielded areas under the curve of 0.72 (95% confidence interval [CI], 0.65 to 0.79) for the SPIROMICS cohort and 0.82 (95% CI, 0.73 to 0.92) for the independent cohort. CONCLUSIONS: Airway mucin concentrations may quantitate a key component of the chronic bronchitis pathophysiologic cascade that produces sputum and mediates disease severity. Studies designed to explore total mucin concentrations in sputum as a diagnostic biomarker and therapeutic target for chronic bronchitis appear to be warranted. (Funded by the National Heart, Lung, and Blood Institute and others.).
Source: New England Journal of Medicine
Authors: Mehmet Kesimer, Amina A. Ford, Agathe Ceppe, Giorgia Radicioni, Rui Cao, C. William Davis, Claire M. Doerschuk, Neil E. Alexis, Wayne H. Anderson, Ashley G. Henderson, R. Graham Barr, Eugene R. Bleecker, Stephanie A. Christenson, Christopher B. Cooper, MeiLan K. Han, Nadia N. Hansel, Annette T. Hastie, Eric A. Hoffman, Richard E. Kanner, Fernando Martinez, Robert Paine, Prescott G. Woodruff, Wanda K. O’Neal, Richard C. Boucher
Institutions: University of North Carolina at Chapel Hill, University of California, San Francisco, Columbia University Irving Medical Center, Wake Forest University, Columbia University, Wake Forest University Health Sciences, University of California San Francisco Medical Center, University of California, Los Angeles, Michigan Medicine, Johns Hopkins University, Johns Hopkins Medicine, University of Iowa Hospitals and Clinics, University of Utah, Weill Cornell Medicine
Language: English
Subfield: Pulmonary and Respiratory Medicine
Field: Medicine
Domain: Health Sciences
Keywords: chronic bronchitis, chronic obstructive pulmonary disease, airway mucin, MUC5AC, MUC5B, induced sputum, mucus transport, smoking, respiratory exacerbations, disease severity, biomarkers, muco-obstructive lung disease, SPIROMICS cohort, size exclusion chromatography, refractive index measurement, mass spectrometry
Open Access status: bronze
Funders: Foundation for the National Institutes of Health, AstraZeneca, GlaxoSmithKline, Sanofi, Ikaria, Chiesi Farmaceutici, Regeneron Pharmaceuticals, Grifols, National Institutes of Health, National Heart, Lung, and Blood Institute, National Institute of Diabetes and Digestive and Kidney Diseases, National Institute of Environmental Health Sciences
Awards: The Impact of Tobacco Exposure on the Lungs Innate Defense System, G2099663897, G2212190077, G3027037974, G3868091120, G3999916299, The role of mucin-protein interactions in the innate defense of the lung, G4578545918, Airway mucus/mucin composition and proteome in COPD: A SPIROMICS ancillary study, G4749522346, G4975107759, G5195001291, G5434367891, G5510456481, G6112557991, G7206313631, SPIROMICS II: Biological underpinnings of COPD heterogeneity and progression, Development of Novel Mycolytic Therapies for Lung Disease, G8251134665, G87279447, G8837091488, G8957911378, Environmental Health Sciences Research Center, Mentoring Research in Precision Medicine for Lung Disease, Precision Medicine Center for Cystic Fibrosis
OpenAlex ID: W2750856487
